Background. Type 2 diabetes (T2D) has been shown to increase dementia risk, but few studies evaluated the relationship between antidiabetic treatment and dementia.
W
ITH increasing life expectancy, the prevalence of diabetes and dementia are rising globally, driven by ageing and increasing age-specific disorders (1, 2) . Type 2 diabetes (T2D) has been demonstrated to be related to accelerated cognitive decline (3) and increased risk of dementia (4) , the pathogenesis of which contains Alzheimer's disease (AD) and vascular dementia. Epidemiologic, imaging, and autopsy studies have shown both cerebrovascular and neurodegenerative mechanisms (5, 6) . As T2D is known to cause cerebrovascular disease (CVD), it is expected to be associated with vascular dementia. Postulated mechanisms of the association between AD and T2D include vascular mechanisms, hyperglycemia, inflammation, hyperinsulinemia, increased levels of cerebral β-amyloid peptides, brain insulin resistance, formation of advanced glycation endproducts, and competition for insulin-degrading enzyme resulting in reduced degradation of β-amyloid peptides (5, 7, 8) .
Given the epidemic of T2D around the world, it is crucial to elucidate the association between T2D and dementia risk, and to determine whether treatment for T2D can reduce dementia risk. Diabetes treatments include lifestyle changes in diet and physical activity, and antidiabetic medications (9, 10) . Because most participants with T2D ultimately take oral antidiabetic medications, it is important to understand the impact of different antidiabetic medications on the development of dementia. Few studies have explored the association between antidiabetic medications and dementia, and their findings remain controversial. Studies showing that metformin (MET) not only reduces insulin levels (11) , inflammation and thrombosis (12) , and the risk of the metabolic syndrome (13) , but also improves insulin sensitivity (11) suggests its potential to exert protective effects on cognitive function. One study in cellular models raises the concern that MET might increase the risk of late onset AD because it shows that MET increases the generation of β-amyloid peptides through upregulation of β-secretase (14) , while a recent study suggests MET and sulfonylureas (SUs) may decrease the risk of dementia (15) . Although the pharmacological mechanisms of thiazolidinediones (TZDs),the potent insulin-sensitizing and anti-inflammatory effects, suggest that they may theoretically decrease the risk of AD, TZDs have been consistently shown to have a higher risk of congestive heart failure, myocardial infarction, and other major cardiovascular adverse effects that all contribute to the development of dementia (16, 17) . One trial found rosiglitazone was effective in memory and attention (18) but another randomized placebo controlled trial and a Phase III trial failed to demonstrate its effectiveness in cognitive function (19, 20) .
In this study, we used samples from the National Health Insurance Research Database (NHIRD) and conducted a population-based analysis of elderly people (65 years or older) in order to investigate the following questions:
1. The risk increased in developing dementia amongst T2D participants. 2. The risk increasing in developing dementia amongst T2D participants receiving particular types of antidiabetic medication.
Methods

Data Sources
The National Health Insurance program in Taiwan is a single-payer compulsory social insurance plan, with a population coverage more than 99%. The National Health Insurance Research Database contains participants' demographic characteristics, including sex, date of birth, place of birth, and diagnoses, undergoing medical or surgical procedures, laboratory tests (results unavailable), medical expenditures, and prescription claims data. Each prescription record contains type of medication, dosage, time of prescription, and refill.
Study Participants
The study was based on the Longitudinal Health Insurance Database 2005, containing the original claim data from 1,000,000 beneficiaries, randomly sampled from the year 2005 Registry for Beneficiaries. Everyone who was a beneficiary of the National Health Insurance Program during any period in 2005 was in the population for random sampling (21) . Data for the birth-year period before 1940 (aged 65 or older) who were dementia-free and T2D-free (detailed definition described later) at baseline (January 2004) were extracted as the geriatric cohort in this study (n = 67,731).
Study Design
The start of the follow-up of the cohort was January 2004. The end of the follow-up was development of dementia, death, or the end of the study in December 2009. We compared development of dementia between T2D and non-T2D participants, and then among T2D participants taking different kinds of antidiabetic medication (Figure 1 ).
There were four main analyses in this study. Analysis one analyzed T2D in relation to dementia, analysis two analyzed the three most common types of antidiabetic agents in relation to dementia, analysis three examined the medication-dementia associations specifically focused on TZDs, and finally analysis four examined the impact of duration of medication use on development of dementia. We followed up the geriatric cohort to observe two main outcomes: (i) the onset of T2D and (ii) the development of dementia. Participants with T2D were participants who had "newonset" T2D from January 2004 to June 2009 (n = 5,420). Then only the new-onset diabetic participants who used solely one type of antidiabetic medication and never used insulin throughout the follow-up period were included in analysis two (n = 1,857), that is, participants using multiple antidiabetic medications or who changed medications during follow-up were excluded (N = 3,563). The 1,857 participants were categorized into three groups by antidiabetic medications: (i) SUs only (n = 796), (ii) MET only (n = 1,033), (iii) TZDs only (n = 28). In analysis three, the associations between use of TZDs and dementia were re-examined by comparing any use of TZDs (n = 841) to never-use of TZDs (n = 4,579) among participants with T2D. Any-use of TZDs was defined as any exposure to TZDs during the follow up, regardless of other types of medication used, and never-use of TZDs was defined as never exposure to TZDs during the follow-up.
Measure of Baseline Criteria and Outcomes
Dementia-free and T2D-free at baseline were defined as no record of a primary diagnosis of disease codes 290.x, 331.0-331.2, 331.7-331.9, or A210 (dementia) and code 250 or A181 (T2D) of the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) within 1 year before January 2004. New-onset T2D was defined as at least two outpatient records of T2D diagnosis within any 1 year with prescription of oral antidiabetic medication for at least three months or at least one inpatient record of T2D diagnosis during the follow-up period for T2D (January 2004 to June 2009). Development of dementia was defined as at least two records of dementia diagnosis within any 1 year during the period from January 2004 to December 2009. Those who developed dementia before the onset of T2D were excluded from the study. Identification of death was according to records of death during the follow-up period in the database.
Covariates
Potential factors contributing to dementia or confounding the medication-dementia associations were collected as covariates in the analyses. The main covariates were T2D, types of antidiabetic medication, and other covariates, including age, sex, cerebrovascular disease (at least three records of ICD-9-CM 430-438 in outpatient diagnosis or one record in inpatient diagnosis), hypertension (at least three records of ICD-9-CM 401-405 plus prescription of antihypertensive agents), hyperlipidemia (at least three records of ICD-9-CM 272), and depression (at least three records of ICD-9-CM codes 296.2, 296.3, 300.4, 311). We did not include chronic kidney disease and all other diabetes associated complications in the analyses because many macro-and microvascular diseases were mutually correlated with one another and also very highly correlated to T2D, and some major complications were not common among our diabetic patient sample.
Statistical Analysis
Comparison of baseline characteristics of study participants by drug usage were analyzed using the chi-squared test (categorical variables) or t test (continuous variables). Cox proportional hazards regression models were used to examine the risk factors for developing dementia associated with T2D (analysis one), types of antidiabetic medication (analysis two and three), and adherence of medication use (analysis four). The time to event was defined using the date of baseline in January 2004 and the end of follow-up (development of dementia or right censored at the end of follow-up) in days. Potential factors that might confound the association were identified and examined initially in univariate models. Significant covariates included in the final model were age, sex, hypertension, hyperlipidemia, and cerebrovascular disease. A 2-sided p value of <.05 was considered statistically significant in this study. KaplanMeier survival curve was used to estimate the probability of dementia survival of the three groups categorized by antidiabetic medication use. SAS 9.2 was used to perform all statistical analyses.
Results
Comparison of Demographic Characteristics and Risk of Dementia Between T2D and Non-T2D Participants (Analysis One)
We followed up 67,731 participants aged 65 or older, who were initially dementia-free, and T2D-free during the period from January 2004 to December 2009 to observe the development of T2D and then dementia. In total, 5,420 participants had new-onset, late-life T2D. For those who had new-onset T2D, the median duration between the time of being included in the study and the diagnosis of T2D was 2.4 years. The rate of dementia in T2D participants was 1.78 cases per 100 person-years (n = 147) which was 1.26 times higher than in non-T2D participants (n = 4,650).
Cox proportional hazards regression analysis showed that the adjusted hazard ratio (HR) of dementia in T2D participants was 1.56 (95% confidence interval (CI): 1.39-2.18) when comparing with non-T2D participants (Table 1) . Prevalent hypertension, cerebrovascular disease, and depression were independently associated with higher dementia risk-HRs were 1.19 (95% CI: 1.13-1.25), 1.44 (95% CI: 1.33-1.56), and 2.12 (95% CI: 1.88-2.39), respectively. Hyperlipidemia was not significantly associated with risk of dementia in the model.
Comparison of Demographic Characteristics and Risk of Dementia Among T2D Participants Taking Different Types of Antidiabetic Medications (Analysis Two)
Among the 5,420 participants with new-onset T2D, 1,857 took solely one type of antidiabetic medication throughout the follow-up period. Among them, SU users tended to be older while TZD users were relatively younger than MET users. Participants with MET were significantly more likely to have hyperlipidemia. Other baseline characteristics, including sex, hypertension, cerebrovascular disease, and depression were similar among the three groups (Table 2) . Kaplan-Meier survival curves between SU group and TZD group and between MET group and TZD group were significantly different (Figure 2 , p value of log-rank test between TZD and MET/SU = .006). At the end of the study, only 39 (3.8%) of the T2D participants taking MET and 40 (5.0%) of the participants taking SUs were diagnosed with dementia, compared with 4 (14.3%) participants taking TZDs.
Using Cox regression and after adjusting for covariates, TZD users had a substantially higher rate of dementia (5.31 [95% CI: 1.89-14.96]) compared to the MET users. The relative rate of dementia was similar in the SU compared to MET users (1.22, 95% CI: 0.78-1.91) ( Table 3) . Hypertension was independently associated with the rate of dementia diagnosis (1.13 [95% CI: 1.09-1.17]), but sex, hyperlipidemia, prevalent cerebrovascular disease, and DM severity were not. Depression was not included in the regression model because of inadequate number of cases.
TZD Risk for Dementia in T2D Participants (Analysis Three)
In the Cox regression analysis comparing any-use of TZDs and never-use of TZDs in participants with T2D, the HR of dementia for TZD users versus nonusers was 1.44 (95% CI: 1.12-1.86) after full adjustment (Table 3 ). The HRs of other covariates in the model were similar to analysis two (data not shown). The corresponding Kaplan-Meier survival plot is provided in Supplementary Figure 1 .
Discussion
Late-life diabetes increased the risk of dementia 1.56-fold, and antidiabetic treatment could affect dementia risk. Among those developing T2D, the rate of dementia was 5.31-fold higher in TZD users compared to MET users. There was no difference in dementia rate among SU users. The results should be interpreted with caution given the observational design of the study, and the relatively small number of TZD users.
This study is unique in that we followed a large-scale, population-based geriatric cohort of diabetes-free and dementia-free participants to the onset of diabetes and then to the development of dementia, investigating the associations of late-life diabetes, and types and compliance of antidiabetic medication in relation to dementia. The analysis focused on participants taking only one type of antidiabetic medication so that the comparison among the three types of antidiabetic medication could be clearer without interference from influences of other types of antidiabetic medication.
The finding that T2D independently increased the risk for dementia was consistent with a review of recent studies concluding that diabetes independently increased the risk of all-cause dementia 1.47-fold (22) . The results of decreased risk of dementia among participants taking SUs and MET compared to TZDs corresponded to a previous study showing that MET and SU treatment reduced the risk of dementia for T2D participants when compared with participants without oral antidiabetic agents (15) . Our study also provided some clues about features of people with late-life onset diabetes, especially the linkage to dementia. It is known that older adults with diabetes are a heterogeneous population that varies in several disease features (23), but current understanding of late-life onset diabetes is actually much less comprehensive than mid-life onset diabetes. As far as we know, only one previous study has discussed the relationship specifically between late-life diabetes and dementia (24) . That study suggested that late-life diabetes increased the risk of dementia as well as mid-life diabetes, but the risk was less strong and more likely to be endogenous. As life expectancy increases globally, late-life diabetes will be more prevalent in the future and merits more attention. Further studies regarding this issue are necessary.
The theoretical positive effects on cognitive function by TZDs, including potent insulin-sensitizing and anti-inflammatory effects, were not supported in our study. Although some studies have shown that use of TZDs might be helpful for cognitive and functional improvement in AD patients (18) , its potential cardiovascular adverse effects raise the risks for vascular dementia and AD. Trials have failed to demonstrate its effectiveness in dementia patients' cognitive function (19, 20) , probably due to its adverse cardiovascular effects outweighing potential benefits. To the best of researchers' knowledge, there was no previous study linking use of TZDs and incident dementia directly, and this study might be the first one to investigate its relationship.
On the other hand, MET and SUs had relatively more positive effects on cognitive function than TZDs. The putative mechanisms of MET's positive effects include (i) reducing insulin levels and improving insulin sensitivity (11), (ii) reducing inflammation (11) , and (iii) reducing the risk of metabolic syndrome (25) . As for SUs, because they act by increasing blood insulin levels, they are not supposed to be advantageous for cognition on a pharmacological basis. A possible explanation for its effects in this study might be that our participants were new-onset T2D participants, who had less insulin resistance, and SUs might temporarily increase brain insulin in the early stage of the disease but do not cause brain insulin resistance. Some limitations of this study should be mentioned. An important limitation is selection bias. Because this was database research rather than a randomized trial, it is inevitable that selection of antidiabetic medication was influenced by patients' clinical medical condition (patient selection bias) and clinical physicians' individual preference (physician selection bias). In other words, a patient might have been more suitable for certain types of medication because of an underlying medical condition, or a clinician could have prescribed a patient certain types of medication because of personal preference. Unfortunately, we did not have data on health condition that might confound the associations, such as HbA1C, drinking or smoking to control for demographic difference and disease severity. Moreover, the sample size was not big enough to do meaningful subgroup analyses stratified by major comorbidities. Nonetheless, these biases should have been minimized by defining the entire diabetic patient sample as all first-onset participants without use of insulin to make the patient characteristics as homogeneous as possible and the medication selection as "fair" as possible. Furthermore, in analysis two, the comparison between antidiabetic drugs was only among participants using a single type of medication throughout the follow-up period. This made the drug comparison more valid, without contamination by other types of medication. Another important limitation was a relatively short follow-up period with regard to a disease with a chronic course like dementia. However, many studies have shown that patients tend to develop dementia in a relatively shorter period of time relative to patients without diabetes. Some of these studies evaluated diabetic risk with incident dementia among old people in a relatively shorter mean follow-up period (ranged 2.1-5.5 years) (4). Our study was with a median follow-up period of 3.1 years from the onset of T2D until the study end. Therefore, we deem it was reasonable to have examined the associations based on the current follow-up period. However, the associations found in this study will surely be more definitive if they could be verified in a study with a longer follow-up time.
These findings add to the growing evidence of a link between T2D, antidiabetic medication, and dementia. In clinical practice, clinicians may take the risk effect of dementia into account in addition to other known antidiabetic effects and contraindications when prescribing oral antidiabetic agents. MET and SUs may have more positive effects on cognitive function over TZDs for T2D participants, and an improved compliance increases the benefits.
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† Only participants with T2D using solely one type of antidiabetic medication and not using insulin throughout the follow-up period were included. These participants were divided into three groups according to types of antidiabetic medication they used.
‡ All participants with T2D treated with oral antidiabetic medication were included. Any-use of thiazolidinediones was defined as any exposure to thiazolidinediones, regardless of use of other types of antidiabetic medication in the follow-up period, and never-use of thiazolidinediones was defined as never exposure to thiazolidinediones during the follow-up.
